Funding
← Back to your selection

4BIO Capital

Activity from announced rounds

Activity in this selectionOct 17, 2026 · Sep 18, 2026
Rounds participated in
3
Confirmed lead rounds
2
All roles disclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$156.4M
3 disclosed · full round size, not this investor’s share

By stage

Seed2
Series A1

By primary sector

Biotech3

By country

Italy1
United Kingdom1
United States1

Rounds

3 in this selection
Estuary Biotherapeutics

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

$93MSeries A
Participant
Undecimal Bio

Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.

$18MSeed
Lead